The story of trastuzumab begins with Axel Ullrich’s dedication to the concept that receptor tyrosine kinases must be the key to many human diseases. It continued with H. Michael Shepard’s dedication to making a cancer therapy that attacks tumour cells, not normal cells, and Dennis Slamon’s drive to save the lives of people with breast cancer.
This is a preview of subscription content, log in via an institution to check access.
References
Sugarman, B. J. et al. Recombinant human tumor necrosis factor-α: effects on proliferation of normal and transformed cells in vitro. Science 230, 943–945 (1985).
Urban, J. L., Shepard, H. M., Rothstein, J. L., Sugarman, B. J. & Schreiber, H. Tumor necrosis factor: a potent effector molecule for tumor cell killing by activated macrophages. PNAS 83, 5233–5237 (1986).
Lewis, G. D., Aggarwal, B. B., Eessalu, T. E., Sugarman, B. J. & Shepard, H. M. Modulation of the growth of transformed cells by human tumor necrosis factor-α and interferon-γ. Cancer Res. 47, 5382–5385 (1987).
Sugarman, B. J., Lewis, G. D., Eessalu, T. E., Aggarwal, B. B. & Shepard, H. M. Effects of growth factors on the antiproliferative activity of tumor necrosis factors. Cancer Res. 47, 780–786 (1987).
Coussens, L. et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 230, 1132–1139 (1985).
Slamon, D. J. et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235, 177–182 (1987).
Hudziak, R. M. et al. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol. Cell. Biol. 9, 1165–1172 (1989).
Fendly, B. M. Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. Cancer Res. 50, 1550–1558 (1990).
Pegram, M. et al. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 18, 2241–2251 (1999).
Stohrer, M., Boucher, Y., Stangassinger, M. & Jain, R. K. Oncotic pressure in solid tumors is elevated. Cancer Res. 60, 4251–4255 (2000).
Carter, P. et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. PNAS 89, 4285–4289 (1992).
Baselga, J. Herceptin® alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: pivotal trials. Oncology 61, 14–21 (2001).
Acknowledgements
I wish to acknowledge Bryan Finkle who always had the utmost confidence that our work would succeed.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
H.M.S is an employee of Enosi Therapeutics, Inc.
Rights and permissions
About this article
Cite this article
Shepard, H.M. Trastuzumab: dreams, desperation and hope. Nat Rev Cancer 24, 287–288 (2024). https://doi.org/10.1038/s41568-024-00676-9
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41568-024-00676-9
- Springer Nature Limited